The current proposed diagnostic and treatment pathways for patients newly diagnosed with ECD, per the consensus guidelines published in 2019, recommends BRAF testing as the first branchpoint in diagnosis [2,8,10]. This evidence concerns the gene BRAF and familial atrioventricular septal defect.